Chimerix, Inc. (NASDAQ:CMRX) Short Interest Update

Chimerix, Inc. (NASDAQ:CMRX) was the target of a large decrease in short interest during the month of March. As of March 15th, there was short interest totalling 3,410,000 shares, a decrease of 27.9% from the February 28th total of 4,730,000 shares. Based on an average trading volume of 3,850,000 shares, the short-interest ratio is currently 0.9 days. Currently, 4.3% of the company’s stock are short sold.

Analyst Upgrades and Downgrades

A number of research firms have recently commented on CMRX. HC Wainwright reiterated a “neutral” rating and issued a $8.55 price objective (down from $11.00) on shares of Chimerix in a research note on Wednesday, March 5th. Wedbush reaffirmed a “neutral” rating and issued a $8.55 price target (up from $7.00) on shares of Chimerix in a research report on Wednesday, March 5th. StockNews.com assumed coverage on Chimerix in a research report on Monday. They issued a “hold” rating for the company. Finally, Jefferies Financial Group reaffirmed a “hold” rating and set a $8.50 target price (down previously from $10.00) on shares of Chimerix in a research report on Wednesday, March 5th.

Chimerix Stock Up 0.1 %

Shares of CMRX stock traded up $0.01 during mid-day trading on Monday, reaching $8.51. The stock had a trading volume of 1,199,988 shares, compared to its average volume of 2,126,445. Chimerix has a one year low of $0.75 and a one year high of $8.53. The firm has a market cap of $797.80 million, a PE ratio of -9.05 and a beta of 0.32. The firm’s 50 day simple moving average is $5.84 and its 200 day simple moving average is $3.12.

Chimerix (NASDAQ:CMRX) last issued its earnings results on Friday, March 21st. The biopharmaceutical company reported ($0.25) EPS for the quarter, topping the consensus estimate of ($0.26) by $0.01. The firm had revenue of $0.06 million during the quarter, compared to the consensus estimate of $0.31 million. Sell-side analysts forecast that Chimerix will post -0.99 earnings per share for the current fiscal year.

Insider Activity

In related news, CEO Michael T. Andriole sold 7,370 shares of the firm’s stock in a transaction on Thursday, February 13th. The shares were sold at an average price of $4.52, for a total value of $33,312.40. Following the transaction, the chief executive officer now directly owns 609,603 shares in the company, valued at approximately $2,755,405.56. This trade represents a 1.19 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. In the last quarter, insiders have sold 20,760 shares of company stock valued at $91,175. Insiders own 13.10% of the company’s stock.

Institutional Trading of Chimerix

A number of institutional investors and hedge funds have recently added to or reduced their stakes in CMRX. Connor Clark & Lunn Investment Management Ltd. lifted its stake in Chimerix by 66.8% during the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 344,712 shares of the biopharmaceutical company’s stock worth $321,000 after purchasing an additional 138,098 shares during the period. Assenagon Asset Management S.A. lifted its position in shares of Chimerix by 154.8% during the 4th quarter. Assenagon Asset Management S.A. now owns 817,739 shares of the biopharmaceutical company’s stock worth $2,846,000 after buying an additional 496,823 shares during the period. Stoneridge Investment Partners LLC boosted its stake in Chimerix by 22.5% in the 4th quarter. Stoneridge Investment Partners LLC now owns 44,305 shares of the biopharmaceutical company’s stock valued at $154,000 after buying an additional 8,134 shares in the last quarter. Peapod Lane Capital LLC acquired a new position in Chimerix during the fourth quarter worth $2,626,000. Finally, Valeo Financial Advisors LLC lifted its holdings in shares of Chimerix by 78.8% during the fourth quarter. Valeo Financial Advisors LLC now owns 146,186 shares of the biopharmaceutical company’s stock valued at $509,000 after acquiring an additional 64,420 shares during the period. Institutional investors own 45.42% of the company’s stock.

About Chimerix

Chimerix, Inc, a biopharmaceutical company, develops medicines to improve and extend the lives of patients facing deadly diseases. Its pipeline products include ONC201 a program that is in Phase 3 clinical trial for treating patients with H3 K27M-mutant diffuse glioma, as well as in Phase 2 clinical trial for the treatment of rare neuroendocrine tumors; and ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic protease P (ClpP) agonist, which is in Phase 1 clinical trial for adult and pediatric patients with primary central nervous system tumors.